Opportunity ID: 338784

General Information

Document Type: Grants Notice
Funding Opportunity Number: W81XWH-22-OCRP-PA
Funding Opportunity Title: DOD Ovarian Cancer Pilot Award
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Cooperative Agreement
Grant
Category of Funding Activity: Science and Technology and other Research and Development
Category Explanation:
Expected Number of Awards: 14
Assistance Listings: 12.420 — Military Medical Research and Development
Cost Sharing or Matching Requirement: No
Version: Synopsis 1
Posted Date: Mar 18, 2022
Last Updated Date: Mar 18, 2022
Original Closing Date for Applications: Aug 05, 2022
Current Closing Date for Applications: Aug 05, 2022
Archive Date: Sep 04, 2022
Estimated Total Program Funding: $5,600,000
Award Ceiling:
Award Floor:

Eligibility

Eligible Applicants: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility”
Additional Information on Eligibility:

Additional Information

Agency Name: Dept. of the Army — USAMRAA
Description:

The OCRP Pilot Award supports the exploration of innovative concepts or theories in ovarian cancer that could ultimately lead to critical discoveries or major advancements that will drive the field forward. The proposed research must demonstrate a clear focus on ovarian cancer (e.g., using tissues, cell lines, datasets, or appropriate animal models), and serve as a catalyst to expand or modify current thinking about and/or approaches in ovarian cancer. If cell lines or animals are to be used, a clear justification should be provided for the choice of proposed cell line(s) or animal model(s).

To foster research with potential to yield new avenues of investigation, preliminary data are not required, but are allowed. Research projects should include a well-formulated, testable hypothesis based on strong scientific rationale; however, applications that demonstrate exceptional scientific merit but lack innovation do not meet the intent of the Pilot Award. The outcome of research supported by this award should be the generation of robust preliminary data that can be used as a foundation for future research projects. Clinical trials will not be supported by this award mechanism.

Innovation: Research deemed innovative may introduce a new paradigm, challenge current paradigms, look at existing problems from new perspectives, or provide new insights, technologies, or applications that have the potential to meet the OCRP mission.

The following list, although not all-inclusive, provides examples of research that are not considered innovative and will likely not be considered for funding under this award mechanism:

• Investigating the next logical step or continuation of a previous research project.

• Proposing work that is an incremental advancement of published data.

• Using a published series of in vitro assays to further characterize a model system.

• Incorporating known biomarkers into in vivo or clinical models of ovarian cancer.

Link to Additional Information:
Grantor Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

CDMRP Help Desk

Phone: 301-682-5507

Email: help@eBRAP.org
Email:help@eBRAP.org

Version History

Version Modification Description Updated Date

Folder 338784 Full Announcement-FY22 OCRP PA -> W81XWH-22-OCRP-PA_GG.pdf

Packages

Agency Contact Information: CDMRP Help Desk
Phone: 301-682-5507
Email: help@eBRAP.org
Email: help@eBRAP.org
Who Can Apply: Organization Applicants

Assistance Listing Number Competition ID Competition Title Opportunity Package ID Opening Date Closing Date Actions
12.420 PKG00272653 Mar 18, 2022 Aug 05, 2022 View

Package 1

Mandatory forms

338784 RR_SF424_5_0-5.0.pdf

338784 AttachmentForm_1_2-1.2.pdf

338784 RR_PersonalData_1_2-1.2.pdf

338784 RR_KeyPersonExpanded_4_0-4.0.pdf

338784 RR_Budget_3_0-3.0.pdf

338784 PerformanceSite_4_0-4.0.pdf

Optional forms

338784 RR_SubawardBudget30_3_0-3.0.pdf

2025-07-12T16:43:27-05:00

Share This Post, Choose Your Platform!

About the Author: